Home>Topics>Companies>Baxter International

Baxter International BAX

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. Headlines
    1. Recent Price Decline Creates An Attractive Entry Point For Halozyme

      Headlines

      Tue, 16 Sep 2014

      FDA's approval of Halozyme and Baxter International 's ( BAX ) HyQvia, on September 13, 2014 ..... at $8.99 - 4.36% down. Baxter and Halozyme have a licensing ..... commercialization of HyQvia, where Baxter funds all the development and

    2. Update: Baxter On A Hot Streak - FDA Approves Rixubis

      Headlines

      Mon, 15 Sep 2014

      June, I wrote a bullish article on Baxter (NYSE: BAX ), with a thesis stating that the ..... also stated that the expansion of Baxter 's ADVATE program into emerging ..... there are underlying risks to a Baxter investment, as the company has reeled

    3. Baxter expands label of hemophilia factor IX

      Headlines

      Mon, 15 Sep 2014

      The FDA approves Baxter International 's ( BAX -0.6% ) Rixubis [Coagulation Factor IX (Recombinant)] for routine the prophylactic treatment, control and prevention of

    4. Halozyme up premarket

      Headlines

      Mon, 15 Sep 2014

      a gap up at the open this morning. Shares are up 6% on healthy volume in response to the FDA's approval of Baxter 's (NYSE: BAX ) Hyqvia [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]. Hyqvia utilizes Halozyme

    5. Update: Baxter Receives Approval For Hyqvia - Growth Prospects Improve

      Headlines

      Sun, 14 Sep 2014

      June, I wrote a bullish article on Baxter (NYSE: BAX ), with a thesis stating that the ..... also stated that the expansion of Baxter 's ADVATE program into emerging ..... there are underlying risks to a Baxter investment, as the company reeled

    6. FDA gives thumbs up to Hyqvia

      Headlines

      Sat, 13 Sep 2014

      The FDA approves Baxter International 's (NYSE: BAX ) Hyqvia [Immune Globulin Infusion 10% (Human) with Recombinant ..... Hyaluronidase increases the dispersion and absorption of IgG. Baxter intends to launch Hyqvia in the U.S. in the next few weeks

    7. New Morningstar Analyst Report for Baxter International Inc

      Stock Reports

      Thu, 11 Sep 2014

      Biogen Idec and Novo Nordisk are taking aim at Baxter 's Advate, and a less-frequent dosing schedule ..... convince physicians and patients to switch from Baxter 's established brand. Baxter shut down its Los Angeles plasma fractionation facility

    8. Baxter names sister company

      Headlines

      Wed, 10 Sep 2014

      traded biopharmaceutical company that Baxter International ( BAX +1.4% ) will form as previously ..... launch sometime in mid-2015. Baxter will continue to trade under the symbol " BAX ." 2 comments!

    9. Update: China Biologic Acquires Additional Interest In Guizhou Facility - Shares Rise

      Headlines

      Tue, 26 Aug 2014

      However, there are underlying risks to an investment in China Biologic, given that the plasma space is home to Baxter (NYSE: BAX ) and Novo Nordisk (NYSE: NVO ), which market internationally ADVATE and NovoSeven, NovoEight and NovoThirteen

    10. Long-acting version of Baxter's hemophilia drug succeeds in study

      Headlines

      Thu, 21 Aug 2014

      Aug 21 (Reuters) - Baxter International Inc said a more potent version of its flagship blood disorder drug Advate met the main goal in a late-stage study.

    « Prev12345Next »
    Content Partners